Adalimumab biosimilar - Boehringer Ingelheim

Drug Profile

Adalimumab biosimilar - Boehringer Ingelheim

Alternative Names: Adalimumab-adbm; BI-695501; Cyltezo

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Panuveitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylitis; Ulcerative colitis

Most Recent Events

  • 08 Dec 2017 Boehringer Ingelheim does not intend to launch its Adalimumab biosimilar in European Union before expiration of the respective SPC for adalimumab in October 2018 (literature review)
  • 08 Dec 2017 Boehringer Ingelheim's Adalimumab biosimilar is not yet commercially available in USA (SC), because the company is engaged in patent litigation with AbbVie (literature review)
  • 13 Nov 2017 Registered for Ankylosing spondylitis (In adults) in European Union, Liechtenstein, Norway, Iceland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top